(Q38169470)

English

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications

scientific article published on 03 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

Ramez N Eskander

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Krishnansu S Tewari

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

0 references

publication date

3 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

132

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

496-505

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Trials with impact on clinical management: first line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Molecular mechanisms of cisplatin resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Normalization of the ovarian cancer microenvironment by SPARC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Tumor microenvironment: what can effusions teach us?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

The role of macrophages and mast cells in lymphangiogenesis and angiogenesis in cervical carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Specific binding of vasculotropin to bovine brain capillary endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Molecular and biological properties of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Role of vascular endothelial growth factor in the regulation of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

VEGF as a therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Vascular-specific growth factors and blood vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

What brings pericytes to tumor vessels?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Overview of anti-angiogenic agents in development for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Experience with bevacizumab in the management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Bevacizumab toxicities and their management in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.11.029

7 January 2021

Identifiers

10.1016/J.YGYNO.2013.11.029

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38169470&oldid=2142339219"